

**Pharmacy Prior Authorization  
Botulinum Toxins – Clinical Guideline**

**Botox** (onabotulinumtoxinA)  
**Dysport** (abobotulinumtoxinA)

**Myobloc** (rimabotulinumtoxinB)  
**Xeomin** (incobotulinumtoxinA)

**Prior Authorization Guidelines for All Indications:**

Botox, Myobloc, Dysport, Xeomin must be prescribed by an appropriate specialist based on indication and meet the following criteria:

- **Migraine Prophylaxis (*Botox*):**
  - Prevention of chronic migraine (at least 15 days per month with headaches lasting 4 hours a day or longer)
  - Member had inadequate response to or intolerable side effects with at least three medications from two classes of migraine headache prophylaxis medication for at least two months (60 days):
    - Beta-blocker: propranolol, metoprolol, timolol, atenolol, nadolol
    - Anticonvulsant: valproic acid or divalproex, topiramate
    - Antidepressants: amitriptyline, venlafaxine
    - Angiotensin-converting enzyme inhibitors (ACE-Is)/angiotensin II receptor blockers (ARBs): lisinopril, candesartan, losartan, valsartan
    - Calcium channel blockers: diltiazem, nifedipine, nimodipine, verapamil
  - Age restriction: must be at least 18 years old
- **Chronic Limb Spasticity (*Botox, Xeomin, Dysport*):**
  - Spasticity may be due to an injury to the brain or spinal cord, or along with a neurological disorder (for example, stroke, traumatic brain injury (TBI), multiple sclerosis (MS), spinal cord injury (SCI), cerebral palsy (CP))
  - Failure of baclofen and at least one other formulary muscle relaxant such as dantrolene. Trial of physical and/or occupational therapy
  - Age restriction (*Botox*): Upper limb and lower limb spasticity: must be at least 18 years old
  - Age restriction (*Dysport* and *Xeomin*): Upper limb spasticity: must be at least 18 years old  
Age restriction (*Dysport*): Lower limb spasticity: must be at least 2 years old
- **Severe primary axillary hyperhidrosis excessive underarm sweating (*Botox*):**

**Pharmacy Prior Authorization  
Botulinum Toxins – Clinical Guideline**

- Interferes with daily activities
- Failure of topical aluminum chloride 20%
- Age restriction: must be at least 18 years old
  
- **Neurogenic bladder (*Botox*):**
  - Diagnosis of urinary incontinence due to detrusor overactivity associated with neurologic condition
  - Trial of behavioral therapy (for example, bladder training, bladder control strategies, pelvic floor muscle training, fluid management) for at least 8-12 weeks
  - Trial and failure of two formulary urinary anticholinergics (for example, oxybutynin, trospium, tolterodine)
  - Age restriction: must be at least 18 years old
  
- **Overactive bladder (*Botox*):**
  - Trial of behavioral therapy (bladder training, bladder control strategies, pelvic floor muscle training, fluid management) for at least 8-12 weeks
  - Trial and failure of two formulary urinary anticholinergics (for example, oxybutynin, trospium, tolterodine)
  - Age restriction: must be at least 18 years old
  
- **Esophageal Achalasia (*Botox*):**
  - Member meets ONE of the following:
    - Member remains symptomatic despite surgical myotomy or pneumatic dilation
    - Member is at high surgical risk or unwilling to undergo surgical myotomy or pneumatic dilation
    - Member presents with atypical achalasia symptoms and Botox is needed to help guide therapy and/or confirm diagnosis
  - Age restriction: must be at least 18 years old
  
- **Chronic anal fissures (*Botox*):**
  - Trial and failure of nitroglycerin ointment 0.4% (Rectiv) AND either bulk fiber supplements, stool softeners, or sitz baths for at least one month
  - Age restriction: must be at least 18 years old

**Pharmacy Prior Authorization  
Botulinum Toxins – Clinical Guideline**

- **Chronic sialorrhea (excessive drooling) (*Botox, Myobloc, or Xeomin*):**
  - Trial and failure of anticholinergic such as glycopyrrolate (pediatric use 3-16) or benztropine (adults)
  - Age restriction (*Botox*): must be at least 21 months old
  - Age restriction (*Xeomin, Myobloc*): must be at least 18 years old
  
- **Focal spasticity or equinus gait due to Cerebral Palsy (*Botox or Dysport*):**
  - Member will be enrolled in or is currently being managed with occupational therapy
  - Age restriction: 2-18 years of age

**Botulinum toxins may also be approved if medically necessary for treatment of the following indications which have limited treatment options:**

- *Botox* for cervical dystonia (also called spasmodic torticollis) in member at least 16 years old
- *Dysport, Myobloc, Xeomin* for cervical dystonia: member is at least 18 years old
- *Botox* for blepharospasm associated with dystonia, including benign essential blepharospasm or VII nerve disorders: member is at least 12 years old
- *Xeomin* for blepharospasm : member is at least 18 years old and previously treated with onabotulinumtoxinA (*Botox*)
- *Botox* for strabismus in member is at least 12 years old
- *Botox* for hemifacial spasm: member is at least 18 years old

**Initial Approval:**

- 6 months
- Treatment should be given every 12 weeks

**Renewal:**

- 1 year
- Treatment should be given once every 12 weeks
- *Botox*: Should not exceed a cumulative dose of 400 units every 90 days

**Pharmacy Prior Authorization  
Botulinum Toxins – Clinical Guideline**

**Additional Information:**

Note: If members do not respond to a course of treatment (usually lasts for 12 weeks), treatment should be discontinued.

Note: Continuing treatment with botulinum toxin injection for ongoing prevention of chronic migraine headaches is considered medically necessary when:

- Migraine headache frequency was reduced by at least 7 days per month (when compared to pre-treatment average) by the end of the initial trial; OR
- Migraine headache duration was reduced by at least 100 total hours per month (when compared to the pre-treatment average) by the end of the initial trial

**References:**

1. Botox (onabotulinumtoxinA) [package insert]. Allergan, Inc, Irvine, CA; May 2018.. [https://www.allergan.com/assets/pdf/botox\\_pi.pdf](https://www.allergan.com/assets/pdf/botox_pi.pdf). Accessed Aug 1, 2018.
2. Dysport (abobotulinumtoxinA) [package insert]. Wrexham, UK: Ipsen Biopharm, Ltd.; 2012. Revised June, 2017.
3. Xeomin (incobotulinumtoxinA) [package insert]. Merz Pharmaceuticals, LLC, Raleigh, NC;; 2010. Revised July, 2018.
4. Myobloc (rimabotulinumtoxinB) [package insert]. South San Francisco, CA: Solstice Neurosciences, Inc.; 2010. Revised Jan, 2010.
5. Simpson DM, Hallet M, Ashman EJ, et al. Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the guideline development subcommittee of the American Academy of Neurology. *Neurology*. 2016;86:1818-1826.
6. Yelnik AP, Simon O, Bensmail D, et al. Drug treatments for spasticity. *Annals Phys Rehab Med*. 2009;52(10):746-756.
7. Brown AL, Gordon J, Hill S. Hyperhidrosis: review of recent advances and new therapeutic options for primary hyperhidrosis. *Curr Opin Pediatr*. 2014;26(4):460-465.
8. International Hyperhidrosis Society. Primary focal axillary. <http://www.sweathelp.org/treatments-hcp/clinical-guidelines/primary-focal-hyperhidrosis/primary-focal-axillary.html>. Accessed August 1, 2018.
9. Solish N, Bertucci V, Dansereau A, et al. A comprehensive approach to the recognition, diagnosis, and severity-based treatment of focal hyperhidrosis: recommendations of the canadian hyperhidrosis advisory committee. *Dermatol Surg*. 2007;33(8):908-923.

**Pharmacy Prior Authorization  
Botulinum Toxins – Clinical Guideline**

10. Evers S, Afra J, Frese A, Goadsby PJ, et al. EFNS guideline on the drug treatment of migraine – revised report of an EFNS task force. *Eur J Neurol*. 2009;16: 968–981.
11. S.D. Silberstein, S. Holland, F. Freitag, et al. Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults. *Neurology* 2012;78;1337-1345.
12. Estemalik E, Tepper S. Preventive treatment in migraine and the new US guidelines. *Neuropsychiatric Disease and Treat*. 2013;9:709–720.
13. Olsson JE, Behrin HC, Forssman B, et al. Metoprolol and propranolol in migraine prophylaxis: a double-blind multicenter study. *Acta Neurol Scand*. 1984;70(3):160-168.
14. Dodick DW, et al. PREEMPT Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. *Headache*. 2010;50(6):921.
15. Tudor KI, Sakakibara R, Panicker JN. Neurogenic lower urinary tract dysfunction: evaluation and management [Published online ahead of print July 11 2016]. *J Neurol*. 2016. DOI: 10.1007/s00415-016-8212-2.
16. Nambiar AA. Chapter 4: guidelines for the diagnosis and treatment of overactive bladder (OAB) and neurogenic detrusor overactivity (NDO). *NeuroUrol Urodyn*. 2014;33(Supp 3):S21-S25.
17. Mahajan ST. Use of botulinum toxin for treatment of non-neurogenic lower urinary tract conditions. UpToDate. <http://www.uptodate.com>. Updated May 16, 2016. Accessed August 11, 2016.
18. Ates F, Vaezi MF. The pathogenesis and management of achalasia: current status and future directions. *Gut Liver*. 2015;9(4):449-463.
19. Vaezi MF, Pandolfino JE, Vela MF. ACG clinical guideline: Diagnosis and management of achalasia. *American Journal of Gastroenterology*. 2013; 108:1238-1249.
20. Wald A, Bharucha AE, Cosman BC, Whitehead WE. ACG clinical guideline: management of benign anorectal disorders. *Am J Gastroenterol*. 2014;109:1141-1157.
21. Breen E, Bleday R. Anal fissure: medical management. UpToDate. <http://www.uptodate.com>. Updated May 18, 2016. Accessed August 12, 2016.
22. Reddihough D, Erasmus CE, Johnson H, McKellar GMW, Jongerius PH. Botulinum toxin assessment, intervention and aftercare for pediatric and adult drooling: international consensus statement. *Eur J Neurol*. 2010;17(Supp 2):109-121.
23. Jongerius PH, van den Hoogen FJA, van Limbeek J, Gabreels FJ, van Hulst K, Rotteveel JJ. Effect of Botulinum Toxin in the Treatment of Drooling: A Controlled Clinical Trial. *Pediatrics*. 2004; 114(3): 620 -627.
24. Reddihough D, Erasmus CE, Johnson H, McKellar GMW, Jongerius PH. Botulinum toxin assessment, intervention and aftercare for pediatric and adult drooling: international consensus statement. *Eur J Neurol*. 2010;17(Supp 2):109-121.
25. Walshe M, Smith M, Pennington L. Interventions for drooling in children with cerebral palsy. *Cochrane DB Syst Rev*. 2012, Issue 11. Art. No.: CD008624. DOI: 10.1002/14651858.CD008624.pub3.
26. Jongerius PH, van den Hoogen FJA, van Limbeek J, Gabreels FJ, van Hulst K, Rotteveel JJ. Effect of Botulinum Toxin in the Treatment of Drooling: A Controlled Clinical Trial. *Pediatrics*. 2004; 114(3): 620 -627.
27. Costa J, et al. Botulinum toxin type A therapy for blepharospasm (Review). *COCHRANE DB SYST REV*. 2004, Issue 2. Art.No.: CD004900. DOI: 10.1002/14651858.CD004900.pub2.

**Pharmacy Prior Authorization  
Botulinum Toxins – Clinical Guideline**

28. Patterson MC. Management and prognosis of cerebral palsy. UpToDate. <http://www.uptodate.com>. Updated April 8, 2016. Accessed August 12, 2016.
29. Pavone V, Testa G, Restivo DA, et al. Botulinum toxin treatment for limb spasticity in childhood cerebral palsy. *Front Pharmacol*. 2016;7:29.
29. Koman LA, Brashear A, Rosenfeld S, et al: Botulinum toxin type a neuromuscular blockade in the treatment of equinus foot deformity in cerebral palsy: a multicenter, open-label clinical trial. *Pediatrics* 2001; 108(5):1062-1071.
30. AbobotulinumtoxinA for equinus foot deformity in cerebral palsy: a randomized controlled trial. 2016;137(2): e20152830.
31. Delgado MR, Hirtz D, Aisen M, et al. Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. *Neuro*. 2010;74(4):336.
32. Hoare BJ, Wallen MA, Imms C, Villanueva E, Rawicki HB, Carey L. Botulinum toxin A as an adjunct to treatment in the management of the upper limb in children with spastic cerebral palsy (update). *Cochrane Database Syst Rev*. 2010;(1): CD003469. doi: 10.1002/14651858.CD003469.pub4.
33. Fehlings D, Rang M, Glazier J, et al: An evaluation of botulinum-A toxin injections to improve upper extremity function in children with hemiplegic cerebral palsy. *The Journal of Pediatrics*. 2000; 137:331-337.
34. Gold Standard. (2016, Jan 26). Botox. Tampa, Florida, USA. Retrieved August 16, 2017, from <http://www.clinicalpharmacology-ip.com/Forms/Monograph/monograph.aspx?cpnum=1219&sec=monindi&t=0>
35. Gormley, EA, Lightner, DJ, Burgio, KL, et al. Diagnosis and Treatment of Overactive Bladder (non-Neurogenic) in Adults:AUA/SUFU guideline. *The Journal of Urology*, 2012: 188 (6), 2455-2463.
36. Egevad. G. Petkova, Y, Villholm, O. Sialorrhea in Patients with Parkinson’s Disease: Safety and Administration of Botulinum Neurotoxin. *Journal of Parkinson’s Disease*. 2014 :4 (3): 321-326.
37. American Academy of Neurology. <https://www.aan.com/Guidelines/home/GetGuidelineContent/377>. Accessed August 2, 2018.
38. National Institute of Neurological Disorders and Stroke. Spasticity information page. <https://www.ninds.nih.gov/Disorders/All-Disorders/Spasticity-Information-Page>. Accessed August 6, 2018.